Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 613 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Function Clear all
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 21, 2026, 12:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
View directory record Official record
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 12:53 PM EDT
Recruiting Phase 1 Interventional

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

NCT04789148
View directory record Official record
Conditions
Vasopressin Deficiency
Interventions
Intranasal Oxytocin (IN-OXT), Placebo
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 2 Interventional Results available

Atrasentan Spermatogenesis and Testicular Function

NCT02118714
View directory record Official record
Conditions
Nephropathy, Diabetes
Interventions
Atrasentan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Laguna Hills, California • Santa Monica, California • Evergreen Park, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 4 Interventional

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

NCT00885820
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, MMF, Corticosteroids (Prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Not applicable Interventional

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

NCT01769963
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Research diet
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 21, 2026, 12:53 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Determination of Kidney Function

NCT00001978
View directory record Official record
Conditions
Kidney Disease, Proteinuria, Autoimmune / Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1989 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Kidney Function

NCT01245790
View directory record Official record
Conditions
Rheumatoid Arthritis, Renal Impairment
Interventions
fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 21, 2026, 12:53 PM EDT
Completed No phase listed Observational

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

NCT03605810
View directory record Official record
Conditions
Renal Function
Interventions
No Intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,132,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 21, 2026, 12:53 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

NCT06962774
View directory record Official record
Conditions
Renal Impairment
Interventions
ESK-001
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Not applicable Interventional

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

NCT02112071
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

NCT04736628
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Avenciguat, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Canyon Country, California • Rancho Cucamonga, California • Victorville, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 21, 2026, 12:53 PM EDT
Completed No phase listed Observational Results available

Real World Glycemic Effectiveness of Linagliptin

NCT03338803
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 21, 2026, 12:53 PM EDT
Completed No phase listed Observational

Comparison of Markers of Kidney Function

NCT01403766
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

NCT01331941
View directory record Official record
Conditions
Advanced Solid Tumors, Kidney Disease, Renal Impairment
Interventions
AMG 386 + Paclitaxel, AMG 386
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Phase 3 Interventional

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

NCT04578834
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
22
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 12:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

NCT02463253
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 82 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 21, 2026, 12:53 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, 68Ga-PSMA-11
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 12:53 PM EDT
Recruiting Phase 2 Interventional

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

NCT06580002
View directory record Official record
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 12:53 PM EDT
Completed No phase listed Observational

New Non-invasive Methods for Real-time Monitoring of Organ Function.

NCT00851851
View directory record Official record
Conditions
Acute Renal Failure, Chronic Renal Failure
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 21, 2026, 12:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.

NCT01978314
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Kidney Injury
Interventions
75 mg / 6 mL VFI™
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
19 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 21, 2026, 12:53 PM EDT